Q1 EPS Forecast for Maze Therapeutics Raised by Analyst

Maze Therapeutics, Inc. (NASDAQ:MAZE) – Analysts at HC Wainwright lifted their Q1 2026 EPS estimates for Maze Therapeutics in a research note issued to investors on Wednesday, March 25th. HC Wainwright analyst A. Ghosh now anticipates that the company will post earnings per share of ($0.62) for the quarter, up from their previous forecast of ($0.73). HC Wainwright currently has a “Buy” rating and a $110.00 price target on the stock. HC Wainwright also issued estimates for Maze Therapeutics’ Q2 2026 earnings at ($0.66) EPS, Q3 2026 earnings at ($0.63) EPS, Q4 2026 earnings at ($0.66) EPS, FY2026 earnings at ($2.57) EPS, FY2027 earnings at ($2.79) EPS, FY2028 earnings at ($0.57) EPS, FY2029 earnings at ($0.04) EPS and FY2030 earnings at $1.00 EPS.

Several other equities research analysts have also recently commented on the company. Mizuho raised Maze Therapeutics to a “strong-buy” rating in a research report on Wednesday, March 11th. BTIG Research restated a “buy” rating and set a $46.00 target price on shares of Maze Therapeutics in a research note on Wednesday. Truist Financial started coverage on shares of Maze Therapeutics in a report on Tuesday, March 17th. They set a “buy” rating and a $68.00 price target on the stock. Weiss Ratings reiterated a “sell (d)” rating on shares of Maze Therapeutics in a research note on Thursday, January 22nd. Finally, Lifesci Capital raised shares of Maze Therapeutics to a “strong-buy” rating in a report on Thursday, December 18th. Three analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus price target of $64.11.

Maze Therapeutics Price Performance

MAZE stock opened at $31.71 on Friday. Maze Therapeutics has a 1-year low of $6.71 and a 1-year high of $53.65. The business has a fifty day moving average price of $45.81 and a 200-day moving average price of $37.51. The stock has a market capitalization of $1.53 billion, a P/E ratio of -9.82 and a beta of 4.47.

Maze Therapeutics (NASDAQ:MAZE) last released its quarterly earnings data on Wednesday, March 25th. The company reported ($0.65) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.73) by $0.08.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the business. Royal Bank of Canada boosted its stake in shares of Maze Therapeutics by 128.3% during the 4th quarter. Royal Bank of Canada now owns 646 shares of the company’s stock worth $27,000 after acquiring an additional 363 shares during the last quarter. Ameritas Investment Partners Inc. increased its stake in shares of Maze Therapeutics by 82.6% in the 3rd quarter. Ameritas Investment Partners Inc. now owns 1,632 shares of the company’s stock worth $42,000 after purchasing an additional 738 shares in the last quarter. California State Teachers Retirement System raised its holdings in Maze Therapeutics by 138.0% in the 4th quarter. California State Teachers Retirement System now owns 1,321 shares of the company’s stock worth $55,000 after purchasing an additional 766 shares during the period. Police & Firemen s Retirement System of New Jersey raised its holdings in Maze Therapeutics by 18.5% in the 4th quarter. Police & Firemen s Retirement System of New Jersey now owns 5,961 shares of the company’s stock worth $247,000 after purchasing an additional 931 shares during the period. Finally, GF Fund Management CO. LTD. purchased a new position in Maze Therapeutics during the fourth quarter valued at $39,000.

Insiders Place Their Bets

In other news, SVP Amy Bachrodt sold 10,000 shares of the company’s stock in a transaction dated Monday, December 29th. The shares were sold at an average price of $40.58, for a total transaction of $405,800.00. Following the completion of the sale, the senior vice president owned 12,965 shares of the company’s stock, valued at $526,119.70. This represents a 43.54% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CMO Harold Bernstein sold 45,000 shares of the stock in a transaction that occurred on Monday, December 29th. The stock was sold at an average price of $40.56, for a total transaction of $1,825,200.00. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 245,000 shares of company stock valued at $10,504,792.

Key Maze Therapeutics News

Here are the key news stories impacting Maze Therapeutics this week:

• Positive Sentiment: HC Wainwright sharply raised its price target to $110 and lifted EPS forecasts across 2026–2030, reiterating a “Buy” rating — a strong fundamental endorsement that supports upside expectations. HC Wainwright Boosts Maze Therapeutics (NASDAQ:MAZE) Price Target to $110.00
• Positive Sentiment: BTIG reaffirmed a “Buy” rating (with a $46 target), providing additional analyst support following the trial news. Maze Therapeutics Earns “Buy” Rating from BTIG Research
• Positive Sentiment: Maze reported positive Phase 2 HORIZON topline data for MZE829, which the company and some analysts called the first clinical proof-of-concept in APOL1-mediated kidney disease — a major clinical milestone that underpins longer-term value. Phase 2 HORIZON topline data article
• Neutral Sentiment: An insider reported the sale of ~15,000 shares (executed via option exercise), disclosed publicly — a liquidity event that can be interpreted various ways but was not described as indicative of corporate problems. Insider sale disclosure
• Negative Sentiment: Despite the positive topline readout, investors sold heavily, and coverage noted the stock plunged roughly one-third at points on “mixed” midstage data interpretation — signaling investor concern about durability, subgroup results, or commercial assumptions. That volatility weighs on near-term price performance. Market reaction / mixed data article
• Negative Sentiment: Investor law firm Johnson Fistel announced an investigation into potential claims involving Maze executives, which can increase regulatory/legal risk and add selling pressure while inquiries are ongoing. Johnson Fistel investigation notice

About Maze Therapeutics

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.